According to Liver Meeting 2017, GS-0976 demonstreated signficant decrease in hepatic fat content and TIMP-1 (a serum marker associated with hepatic fibrosis)
While Novo Nordisk and Eli Lilly currently dominate the GLP-1 market, other major players are quickly entering the space
The survey, which included a nationally representative group of 8,793 adults, revealed that 11.8% have already used GLP-1 agonists
PlexusDx distinguishes between these scenarios by evaluating your current appetite levels, medication adherence, dietary consistency, and physical activity
Experts say the African market is rapidly expanding as companies seek to cash in on the continents booming youth population
Studies have used different approaches, with good results from 500 mg/day over 4 weeks [23]